Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Avadel Pharmaceuticals PLC
Total Receivables
Avadel Pharmaceuticals PLC
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Total Receivables
$42.4m
|
CAGR 3-Years
159%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
23%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Total Receivables
$650.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-6%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Total Receivables
$830.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
15%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Total Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Total Receivables
€50.1m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Total Receivables
€58k
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-24%
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Total Receivables?
Total Receivables
42.4m
USD
Based on the financial report for Sep 30, 2025, Avadel Pharmaceuticals PLC's Total Receivables amounts to 42.4m USD.
What is Avadel Pharmaceuticals PLC's Total Receivables growth rate?
Total Receivables CAGR 10Y
23%
Over the last year, the Total Receivables growth was 14%. The average annual Total Receivables growth rates for Avadel Pharmaceuticals PLC have been 159% over the past three years , -2% over the past five years , and 23% over the past ten years .
